Balasa R W, Murray R L, Kondelis N P, Bischel M D
Nephron. 1987;45(1):16-21. doi: 10.1159/000184064.
The phosphate-binding capacities of 19 liquid and solid aluminum hydroxide gel antacids were determined in vitro under varying pH conditions. The resulting data provide a basis explaining the phosphate-binding characteristics observed when patients are treated with long-term aluminum hydroxide therapy. No antacid, liquid or solid, showed significant binding at pH 1.0. Maximum phosphate binding (expressed as phosphorus; P) was observed at pH 2.0 and 3.0 for most antacids and decreased markedly at alkaline pH. The liquid antacids showed a significantly greater phosphate-binding capacity than did tablets or capsules (p less than 0.01). At pH 2.0, the liquid antacids bound a mean of 22.3 mg P/5 ml. At pH 8.0 binding was reduced to a mean of 7.3 mg P/5 ml. Significant interbrand differences were observed. At pH 2.0, the solid antacids bound a mean of 15.3 mg P/tablet or capsule. At pH 8.0, binding was reduced to a mean of 5.8 mg P/tablet or capsule. Interbrand differences, while substantial, were less than those observed among the liquid antacids. Variations in sodium and potassium content were clinically insignificant for most of the antacids in this study, while the differences in phosphate-binding properties were sufficient to warrant attention in the patient with renal failure.
在不同pH条件下，对19种液体和固体氢氧化铝凝胶抗酸剂的磷酸盐结合能力进行了体外测定。所得数据为解释患者接受长期氢氧化铝治疗时观察到的磷酸盐结合特性提供了依据。在pH 1.0时，无论是液体还是固体抗酸剂均未显示出显著的结合作用。大多数抗酸剂在pH 2.0和3.0时观察到最大磷酸盐结合量（以磷表示；P），而在碱性pH条件下显著降低。液体抗酸剂的磷酸盐结合能力明显高于片剂或胶囊（p小于0.01）。在pH 2.0时，液体抗酸剂平均结合22.3 mg P/5 ml。在pH 8.0时，结合量降至平均7.3 mg P/5 ml。观察到显著的品牌间差异。在pH 2.0时，固体抗酸剂平均结合15.3 mg P/片或胶囊。在pH 8.0时，结合量降至平均5.8 mg P/片或胶囊。品牌间差异虽然很大，但小于液体抗酸剂之间的差异。本研究中大多数抗酸剂的钠和钾含量变化在临床上无显著意义，而磷酸盐结合特性的差异足以引起肾衰竭患者的关注。
